Abstract
Sialidosis type 1 is a rare autosomal recessive disease, considered among the progressive myoclonous epilepsies (PME) and characterized by cortical myoclonous, seizures, ataxia, macular cherry-red spot and visual defects1. Recent clinical studies show a significative effectiveness of Perampanel (PER) on myoclonous and seizures in some cases of PME2,3. We describe a comprehensive clinical, neuroradiological, electrophysiological and ophtalmological long-term follow-up of two unrelated patients affected by Sialidosis type 1. Furthermore, we assess the effectiveness on myoclonous and tolerability of PER in add-on.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
